vimarsana.com

Latest Breaking News On - Ncannex healthcare kurs - Page 1 : vimarsana.com

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

17.01.2024 - MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.